Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNEX Vaccine
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Partnering
Bio Defense
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map

Immune Response BioPharma, Inc. TM  © 2010-2014

The Vaccine Development Company for the 21st Century & Beyond 

Home Page
undefinedundefined

Auto-Immune & Infectious Disease Drug Discovery & Research
Mission to Become the World Leader In Saving Lives & Vaccine Technology
 
Drug Discovery Pipeline
NeuroVax TM First in Class MS Vaccine FDA FastTrack   
Sepsicillin TM  First in Class Sepsis Drug 
REMUNE TM  First in Class Rescue HIV/AIDS Vaccine
RemuneX TM     Next Generation HIV/AIDS Vaccine
RemuneVax TM  Next Generation HIV/AIDS Vaccine
RAVAX TM            First in Class RA Vaccine
DermaVax TM  First in Class Eczema Vaccine
ZORCELL TM First in Class Psoriasis Vaccine
 
NeuroVax Granted FDA Pediatric Orphan Designation 
& FDA Fast Track Designation for SPMS
REMUNE Granted FDA Pediatric Orphan Designation 
 
 
 
Immune Response BioPharma, Inc. TM
 All Rights Reserved
                                                                           




  
Copyright © 2010-2014